Immunochemotherapy for intracellular leishmania donovani infection: γ interferon plus pentavalent antimony

Journal of Infectious Diseases

Volumn 157, Issue 5, 1988, Pages 973-978

  Murray, Henry W ^a,b   Berman, Jonathan D ^a,b   Wright, Samuel D ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; STIBOGLUCONATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LEISHMANIA DONOVANI; LEISHMANIASIS; MACROPHAGE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTOZOON;

ANIMAL; ANTIMONY SODIUM GLUCONATE; GLUCONATES; HUMAN; IMMUNOTHERAPY; INTERFERON TYPE II; LEISHMANIASIS, VISCERAL; MACROPHAGES; MICE; MICE, INBRED BALB C; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023935522     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/157.5.973     Document Type: Article

References (21)

1. Murray HW, Rubin BY, Rothermel CD. Killing of intracellular Leishmania donovani by lymphokine-stimulated human monoclear phagocytes. Evidence that interferon-γ is the activating lymphokine. J Clin Invest 1983;72:1506-10
2. Murray HW, Spitalny GL, Nathan CF. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-y. J Immunol 1985;134:1619-22
3. Hoover DL, Nacy CA, Meltzer MS. Human monocyte activation for cytotoxicity against intracellular Leishmania donovani amastigotes: Induction of microbicidal activity by interferon-γ. Cell Immunol 1985;94:500-11
4. Murray HW, Masur H, Keithty JS. Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity. J Immunol 1982;129: 344-50
5. Murray HW, Stern JJ, Welte K, Rubin BY, Carriero SM, Na than CF. Experimental visceral leishmaniasis: Production of interleukin 2 and interferon-y, tissue immune reaction, and response to treatment with interleukin 2 and interferon-γ. J Immunol 1987;138:2290-7
6. Ho M, Koech DK, Iha DW, Bryceson ADM. Immunosuppression in Kenyan visceral leishmaniasis. Clin Exp Immunol 1983;51:207-14
7. Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WD Jr. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 1985;76:2066-9
8. Sacks DL, Lai SL, Shrivastava SN, Blackwell J, Neva FA. An analysis of T cell responsiveness in Indian Kala-Azar. J Immunol 1987;138:908-13
9. Nathan CF. Interferon-gamma and macrophage activation in cell-mediated immunity. In: Steinman RM, North RJ, eds. Mechanisms of host resistance to infectious agents, tumors, and allografts. New York: Rockefeller University Press, 1986:165-84
10. McCabe RE, Luft BJ, Remington JS. Effect of murine interferon-γ on murine toxoplasmosis. J Infect Dis 1984; 150:961-2
11. Edwards CK III, Hedegaard HB, Zlotnik A, Gangadharam, PR, Johnston RB Jr, Pabst MJ. Chronic infection due to Mycobacterium intracellulare in mice: Association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or inter-feron-γ. J Immunol 1986;136:1820
12. Nathan CF, Horowitz CR, de al Harpe J, Vadhan-Raj S, Sher-win SA, Oettgen HF, Krown SE. Administration of recombinant interferon-y to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci USA 1985;82:8686-90
13. Nathan CF, Kaplan G, Levis WR, Nusrat A, Witmer MD, Sherwin SA, Job CK, Horowitz CR, Steinman RM, Cohn ZA. Local and systemic effects of intradermal recombinant interferon-y in patients with lepromatous leprosy. N Engl J Med 1986;315:6-15
14. Murray HW, Scavuzzo D, Jacobs JL, Kaplan MH, Libby DM, Schindler J, Roberts RB. In vitro and in vivo activation of human mononuclear phagocytes by interferon-γ. Studies with normal and AIDS monocytes. J Immunol 1987;138: 2457-62
15. Berman JD, Chulay JD, Hendricks LD, Oster CN. Susceptibility of clinically sensitive and resistant Leishmania to pen-tavalent antimony in vitro. Am J Trop Med Hyg 1982; 31:459-65
16. Wright SD, Silverstein SC. Tumor-promoting phorbol esters stimulate C3b and C3b’ receptor-mediated phagocytosis in cultured human monocytes. J Exp Med 1982;156:1149-64
17. Bryceson ADM, Chulay JD, Ho M, Mugambii M, Were JB, Muigai R, Chunge C, Gachihi G, Meme J, Anabwani G, Bhatt SM. Visceral leishmaniasis unresponsive to an-timonial drugs. I. Clinical and immunological studies. Trans R Soc Trop Med Hyg 1985;79:700-4
18. Bryceson ADM, Chulay JD, Mugambi M, Were JB, Gachihi G, Chunge CN, Muigai R, Bhatt SM, Ho M, Spencer HC, Meme J, Anabwani G. Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Trans R Soc Trop Med Hyg 1985;79:705-14
19. Chunge CN, Gachihi G, Muigai R, Wasunna K, Rashid JR, Chulay JD, Anabwani G, Oster CN, Bryceson ADM. Visceral leishmaniasis unresponsive to antimonial drugs. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg 1985;79:715-8
20. Haidaris CG, Bonventre PF. Efficacy of combined immuno-stimulation and chemotherapy in experimental visceral leishmaniasis. Am J Trop Med Hyg 1983;32:286-95
21. Adinolfi LE, Bonventre PF, Vander Pas M, Eppstein DA. Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis. Infect Immun 1985;48:409-16